OverviewSuggest Edit

TG Therapeutics is an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the Company is developing two therapies targeting hematological malignancies: TG-1101 (ublituximab) is a novel, glycoengineered, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes and TGR-1202, an orally available Phosphoinositide 3-kinase delta inhibitor.

TypePublic
Founded1993
HQNew York, US
Websitetgtherapeutics.com

Latest Updates

Employees (est.) (Feb 2019)105(+40%)
Revenue (FY, 2016)$152.4 K
Share Price (Oct 2019)$5.4

Key People/Management at TG Therapeutics

Michael S. Weiss

Michael S. Weiss

Executive Chairman, Interim President and CEO
Sean A. Power

Sean A. Power

CFO
Show more

TG Therapeutics Office Locations

TG Therapeutics has an office in New York
New York, US (HQ)
2 Gansevoort St
Show all (1)

TG Therapeutics Financials and Metrics

TG Therapeutics Revenue

TG Therapeutics's revenue was reported to be $152.38 k in FY, 2016
USD

Net income (Q2, 2019)

36.2m

EBIT (Q2, 2019)

35.5m

Market capitalization (16-Oct-2019)

508.4m

Closing stock price (16-Oct-2019)

5.4

Cash (30-Jun-2019)

57.2m

EV

479.6m
TG Therapeutics's current market capitalization is $508.4 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

152.4k152.4k152.4k152.4k

Revenue growth, %

R&D expense

13.7m40.1m47.7m69.2m

Operating expense total

13.7m40.1m47.7m69.2m118.9m174.6m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Operating expense total

17.1m13.9m14.0m16.1m27.7m28.5m31.6m40.6m44.4m34.4m34.7m35.6m

EBIT

(14.6m)(17.1m)(13.8m)(14.0m)(16.0m)(24.9m)(27.7m)(28.4m)(31.6m)(41.6m)(44.3m)(34.3m)(34.7m)35.5m

Interest expense

237.7k246.5k246.5k242.4k220.8k211.5k1.1m

Interest income

22.1k31.6k56.0k84.9k92.6k88.0k44.7k50.2k79.2k144.0k189.0k258.0k149.0k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

40.5m55.7m55.1m25.0m56.7m42.0m

Accounts Receivable

27.2k85.5k186.0k83.9k108.5k95.0k

Inventories

Current Assets

42.3m85.2m86.9m50.9m93.3m79.0m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

50.2m49.6m37.1m53.2m86.0m60.3m65.5m36.5m28.6m29.2m95.6m77.6m91.8m82.9m105.7m70.7m64.3m57.2m

Accounts Receivable

11.1k74.7k53.8k89.7k190.3k158.5k164.1k133.8k108.5k22.8k43.3k79.0k87.0k80.0k

Current Assets

50.6m56.3m49.3m76.7m115.7m103.7m104.7m70.6m69.6m71.3m119.0m97.0m97.7m117.0m136.0m109.7m105.1m94.4m

PP&E

69.2k323.0k333.9k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(20.5m)(55.8m)(62.9m)(78.3m)

Depreciation and Amortization

1.1k3.9k15.5k63.0k82.4k88.0k

Inventories

Accounts Payable

Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

(14.6m)(17.1m)(13.7m)(13.8m)(29.7m)(24.8m)(27.7m)(56.1m)(87.6m)(41.5m)(85.7m)(119.6m)(35.2m)71.4m

Depreciation and Amortization

634.0706.01.6k2.5k5.8k10.3k6.4k23.3k20.4k41.1k62.0k20.0k41.0k64.0k23.0k46.0k

Accounts Payable

1.9m8.0m8.9m8.3m8.6m8.1m13.1m15.6m18.9m

Cash From Operating Activities

(5.9m)(8.3m)(11.9m)(20.0m)(21.1m)(31.8m)(16.7m)(29.5m)(22.3m)(49.1m)(71.9m)(28.0m)(62.2m)(95.2m)(33.4m)(69.2m)
USDY, 2019

EV/EBIT

13.5 x

EV/CFO

-6.9 x

Financial Leverage

8.1 x
Show all financial metrics

TG Therapeutics Online and Social Media Presence

Embed Graph

TG Therapeutics News and Updates

TG Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

Presentation scheduled for today, Wednesday, October 2, 2019 at 4:10 PM ET Presentation scheduled for today, Wednesday, October 2, 2019 at 4:10 PM ET

TG Therapeutics Announces Publication of Clinical Data from the Phase I/Ib Combination Trial of Ublituximab and Umbralisib (“U2”) in Blood

U2 combination was generally well-tolerated with relatively low rates of immune-mediated toxicities

TG Therapeutics Announces Data Presentations at the XVIII International Workshop on Chronic Lymphocytic Leukemia (iwCLL)

Phase 2 study of umbralisib monotherapy in BTK/PI3K-delta intolerant CLL reports an estimated median progression-free survival (PFS) of 23.5 months (n=50) with 58% of patients on umbralisib longer than their prior kinase inhibitor therapy

TG Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference

Presentation scheduled for Tuesday, September 24, 2019 at 11:00 AM ET Presentation scheduled for Tuesday, September 24, 2019 at 11:00 AM ET

TG Therapeutics Presents Data for Ublituximab at the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

NEW YORK, Sept. 12, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today presented the first look at the ULTIMATE I & II Phase 3 trial design and demographic data and updated Phase 2 extension trial data for ublituximab, the Company’s novel, glycoengineered anti-CD20 monoclonal…

TG Therapeutics Announces Data Presentations at the Upcoming 35th Annual Congress of ECTRIMS

Presentations include Phase 3 ULTIMATE program study design and patient demographic information, and long-term safety data from the Phase 2 trial of ublituximab in MS Presentations include Phase 3 ULTIMATE program study design and patient demographic information, and long-term safety data from the P…
Show more

TG Therapeutics Blogs

TG Therapeutics Mourns the Loss of Board Member, Mark Schoenebaum, MD

NEW YORK , Aug. 26, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) announced with great sadness the passing of longtime Board Member, Mark Schoenebaum , MD. "Everyone at TG is incredibly saddened by the loss of Mark Schoenebaum . He was one of our first Directors, joining us in 2012,

TG Therapeutics to Host Conference Call on Second Quarter 2019 Financial Results and Business Update

Conference Call to be held Friday, August 9, 2019 at 8:30 AM ET NEW YORK , Aug. 07, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Friday, August 9, 2019 at 8:30 AM ET to discuss results for the second quarter of 2019 and provide

TG Therapeutics Announces Presentation of Long-term Follow-up Data from the Phase 2 Trial of Ublituximab in Patients with Multiple Sclerosis During an Oral Session at the 5th Congress of the European Academy of Neurology

Ublituximab treatment continues to be well tolerated with a median duration of follow-up of 97.5 weeks NEW YORK , July 02, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company dedicated to developing medicines for patients with B-cell mediated diseases, today

TG Therapeutics Announces Data Presentations at the 15th International Conference on Malignant Lymphoma

TG Therapeutics Announces Data Presentations at the 15th International Conference on Malignant Lymphoma Content Import Thu, 06/20/2019 - 09:06 TG Therapeutics Announces Data Presentations at the 15th International Conference on Malignant Lymphoma Jun 20, 2019 …

TG Therapeutics Presents Positive Interim Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the 55th American Society of Clinical Oncology (ASCO) Annual Meeting

Overall response rate ( ORR ) of 52% (N=42), with complete response (CR) rate of 19%, by central independent review committee (IRC)  Umbralisib was well tolerated with a safety profile that appeared to be maintained with prolonged exposure NEW YORK , June 04, 2019 (GLOBE NEWSWIRE) -- TG

TG Therapeutics Reports Positive Interim Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the 2019 AACR Annual Meeting

TG Therapeutics Reports Positive Interim Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the 2019 AACR Annual Meeting Content Import Mon, 04/01/2019 - 08:38 TG Therapeutics Reports Positive Interim Data from UNITY-NHL Phase 2b…
Show more

TG Therapeutics Frequently Asked Questions

  • When was TG Therapeutics founded?

    TG Therapeutics was founded in 1993.

  • Who are TG Therapeutics key executives?

    TG Therapeutics's key executives are Michael S. Weiss and Sean A. Power.

  • How many employees does TG Therapeutics have?

    TG Therapeutics has 105 employees.

  • Who are TG Therapeutics competitors?

    Competitors of TG Therapeutics include GT Biopharma, Athersys and Reata Pharmaceuticals.

  • Where is TG Therapeutics headquarters?

    TG Therapeutics headquarters is located at 2 Gansevoort St, New York.

  • Where are TG Therapeutics offices?

    TG Therapeutics has an office in New York.

  • How many offices does TG Therapeutics have?

    TG Therapeutics has 1 office.